



KOLINPHARMA®
LEADER TO HEALTH

KOLINPHARMA®: REVENUE +98% AT EURO 2.7 MILLION IN THE FIRST HALF-YEAR

Number of medical prescriptions increasing by 49%

Milan, August 6th 2018

KOLINPHARMA®, Innovative SME operating in the nutraceutical sector, reports that it examined the preliminary management information concerning the first six months of the year in relation to revenue and medical prescriptions.

In particular, in the first half-year 2018, Kolinpharma's revenues are more than doubled compared to the same period of the previous year, passing from Euro 1.4 to 2.7 million.

Moreover, the total number of prescription is increasing by 49% compared to the same period of the previous year, for a total of 180,836 (121,319 in 2017).

As of June 30th, 2018 the medical-scientific representatives (MSRs) are 67; therefore, the strategy of strengthening the network is going on compared to the 37 MSRs as of December 31st 2017 and to the 63 of the first quarter of 2018.

"We are very satisfied of the results achieved of this first half-year, because they demonstrates how our growth and development path is giving us tangible results" commented the CEO Emanuele Lusenti.

"The double-digit growth of all main economic indicators is a confirmation of the great potential of our reference market and that we want control with more and more effectiveness. As represented in the Admission Document, Kolinpharma's revenues are linked to the seasonality of the orders and these don't contribute uniformly to the results" (look at chapter 4, part I of the Admission Document available on the website, Investor Relations section, paragraph 4.1.9).

Recall that the data indicated in this press release are based on management accounts and that they aren't audited by the appointed auditing firm BDO yet.

This press release is available online on the corporate website www.kolinpharma.com, in the section Investor Relations > Financial Press Releases.

KOLINPHARMA® S.p.A., founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made of innovative and natural raw materials and have the purpose of supporting the pharmacological treatments mainly for the diseases in the orthopaedic-physiatric and gynaecological fields. **KOLINPHARMA** distributes the products with its brand in the whole Italian territory through a skilled sales network of 66 medical-scientific representatives (MSRs), specialised sole agents graduated in scientific disciplines. The MSRs promote **KOLINPHARMA**'s nutraceutical products directly to doctors, pointing at the specialists' awareness. The Company's direct clients are wholesalers, that distribute to pharmacies and para-pharmacies throughout Italy. **KOLINPHARMA** owns 4 patents in Italy and 9 certifications, of which 2 on the company and 7 on its products.

Contacts

IR TOP Consulting S.r.l
Capital Markets & Investor Relations
Floriana Vitale, Domenico Gentile
f.vitale@irtop.com, d.gentile@irtop.com
Via C. Cantù, 1 - 20123 Milan
Tel.: +39 02 4547 3883/4

EnVent Capital Markets Ltd.
Nominated Adviser (NOMAD)
Francesca Martino
fmartino@enventcapitalmarkets.co.uk
42 Berkeley Square - London W1J 5AW Italian
Branch, via Barberini n. 95 - 00187 Rome
Tel.: +39 06 896841 Fax: +39 06 89684155

